Use of the LEVA® Pelvic Health System for Fecal Incontinence

Last updated: October 13, 2025
Sponsor: University of Wisconsin, Madison
Overall Status: Active - Not Recruiting

Phase

4

Condition

Rectal Disorders

Fecal Incontinence

Bowel Dysfunction

Treatment

The Leva Pelvic Health System

Clinical Study ID

NCT06152224
2023-1304
Protocol Version 10/12/2023
SMPH/OBGYN BENIGN GYN
A532810
Protocol Version 10/1/2024
  • Ages > 18
  • Female

Study Summary

The goal of this clinical trial is to learn about how the duration of use of The Leva Pelvic Health System® affects treatment of fecal incontinence in women. The main question it aims to answer is to test whether use of the The Leva Pelvic Health System® for 8 weeks is as good as using it for 16 weeks.

Participants will complete surveys, and use the Leva device.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult, age ≥ 18years, assigned female at birth

  • Fecal incontinence, defined as any uncontrolled loss of liquid or solid fecalmaterial that occurs at least monthly over the last 3 months that is bothersomeenough to desire treatment

  • Able to stand to perform daily training for at least 3 minutes

  • Able to speak and read English due to Leva smartphone application availability inonly English at this time

  • Have an email address, owns a smartphone, and can download an app

Exclusion

Exclusion Criteria:

  • Inability to tolerate insertion of vaginal device (e.g., vaginal agenesis, vaginalstenosis, unremitting pelvic pain, within 12 weeks postpartum)

  • Current diagnosis of colorectal or anal malignancy

  • Diagnosis of uncontrolled inflammatory bowel disease

  • Current rectovaginal fistula or cloacal defect

  • Rectal prolapse (mucosal or full thickness)

  • Inability to utilize smart phone technology ("app" use)

  • Chronic Stool Types 6 or 7

  • Fecal impaction by exam

  • Stage 4 pelvic organ prolapse

  • Concurrent supervised anal sphincter exercise/pelvic floor muscle training with orwithout biofeedback

  • Presence of sacral neuromodulator

  • Pelvic floor surgery (including anal sphincteroplasty) within the past 3 months

  • Currently pregnant

Study Design

Total Participants: 38
Treatment Group(s): 1
Primary Treatment: The Leva Pelvic Health System
Phase: 4
Study Start date:
January 17, 2024
Estimated Completion Date:
September 30, 2026

Study Description

This study will assess whether 8 weeks of use of the Leva Pelvic Health System (Leva) is non-inferior to 16 weeks of use for the treatment of chronic fecal incontinence (symptoms >/= 3 months) in adults with a vagina. Participants will be instructed to complete pelvic floor muscle training using the Leva for 8 or 16 weeks.

The hypothesis is that 8 weeks of use of Leva is non-inferior to 16 weeks of use, assessed by a validated FI symptom severity survey. Surveys will be completed at 0 weeks, 16 weeks, and 24 weeks. Long-term surveys will be completed at 1 year and 2 years from enrollment.

Connect with a study center

  • University of Wisconsin

    Madison, Wisconsin 53705
    United States

    Site Not Available

  • University of Wisconsin

    Madison 5261457, Wisconsin 5279468 53705
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.